Adaptimmune up on agreement with GSK for transfer of cell therapy programs

Adaptimmune Therapeutics

11/04/2023 15:17

** U.S.-listed shares of cancer therapies developer
Adaptimmune Therapeutics  ADAP.O  gain ~3% to $1.17
    ** Company enters into a transition agreement with GSK Plc
 GSK.L  for transfer of some cell therapy programs back to
Adaptimmune
    ** ADAP had said in October that GSK would transfer its
NY-ESO cell therapy program and the right to the PRAME cell
therapy program to Adaptimmune
    ** Adaptimmune will receive £30 mln ($37.28 mln) in relation
to the transition of ongoing NY-ESO clinical trials, company
said on Tuesday
    ** U.S.-listed ADAP shares down ~20% YTD


($1 = 0.8047 pounds)

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))